Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)

What is it about?

The hormone glucagon normally lowers the hepatic secretion of lipids to the blood. This study shows that glucagon does not function normally in individuals with obesity-related fatty liver disease, perhaps adding to the elevated plasma lipids and cardiovascular risk in these individuals.

Featured Image